therapeutics

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed…

1 day ago

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…

4 days ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

January 23, 2026 09:00 ET  | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) --…

1 week ago

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

January 20, 2026 17:31 ET  | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics,…

2 weeks ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:05 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…

2 weeks ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:05 ET  | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”…

2 weeks ago

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing…

3 weeks ago

Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics

Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with…

3 weeks ago

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis

Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors January 08, 2026…

3 weeks ago

Day One Completes Acquisition of Mersana Therapeutics

Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma…

4 weeks ago